Skip to main content
SpringerLink
Log in

Docetaxel cost effective as second-line therapy in NSCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Docetaxel cost effective as second-line therapy in NSCLC. Pharmacoecon. Outcomes News 357, 3 (2002). https://doi.org/10.1007/BF03278895

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03278895

Keywords

Search

Navigation